28bio's Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability

Results show 83% sensitivity and 89% specificity in predicting whether small molecule drugs will cause clinical seizures CNS-3D Brain Organoids are 13x more predictive than animal models Data from 120 ...

Lantern receives FDA clearance for paediatric STAR-001 CNS trial

Starlight Therapeutics' wholly owned subsidiary Lantern Pharma has secured the US Food and Drug Administration (FDA) ...

Belay Diagnostics Reports 82% Clinical Impact Rate for Summit(TM) and Vantage(TM) in CNS Lymphoma Study

Belay Diagnostics announced the publication of a new retrospective study demonstrating that its Summit and Vantage tests provided meaningful clinical impact in 82% of CNS lymphoma cases evaluated. The ...
ascopubs.org

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...